Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology; Hubei Clinical Research Centre for Infectious Diseases; Wuhan Research Centre for Communicable Disease Diagnosis and Treatment, Chinese Academy of Medical Sciences; Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology and Wuhan Jinyintan Hospital, Chinese Academy of Sciences, Wuhan, 430023, China.
J Int Med Res. 2023 Jan;51(1):3000605221148416. doi: 10.1177/03000605221148416.
To investigate if the addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis (MDR-TB) could improve patient outcomes.
A prospective, randomized, controlled study was conducted in patients with MDR-TB. Treatment was for 18 months. Patients in the experimental group received bedaquiline and clofazimine in addition to their regular treatment regimen whereas patients in the control group did not.
68 patients with MDR-TB were randomised to treatment, 34 to each group. At the end of treatment, cure rates were statistically significantly greater for the experimental group compared with the control group (82% vs. 56%). There was no difference between groups in the number of severe adverse events (3[9%]) in both groups and none were skin-related.
The addition of bedaquiline and clofazimine to the treatment regimen significantly improves outcomes for patients with MDR-TB. Clinicians should be aware of the clinical benefits of this addition but be mindful of contraindications and adverse effects.
研究在耐多药结核病（MDR-TB）治疗方案中添加贝达喹啉和氯法齐明是否能改善患者结局。
对 MDR-TB 患者进行前瞻性、随机、对照研究。治疗时间为 18 个月。实验组患者在常规治疗方案的基础上接受贝达喹啉和氯法齐明治疗，而对照组患者则不接受。
68 例 MDR-TB 患者随机分组治疗，每组 34 例。治疗结束时，实验组的治愈率明显高于对照组（82%比 56%）。两组严重不良事件（3[9%]）的数量无差异，且均与皮肤无关。
在治疗方案中添加贝达喹啉和氯法齐明显著改善了 MDR-TB 患者的结局。临床医生应意识到这种添加的临床益处，但要注意禁忌证和不良反应。
